40.91
1.71 (4.36%)
| Previous Close | 39.20 |
| Open | 39.90 |
| Volume | 294,505 |
| Avg. Volume (3M) | 694,651 |
| Market Cap | 2,387,867,648 |
| Price / Book | 3.68 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Diluted EPS (TTM) | -3.61 |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 15.82 |
| Operating Cash Flow (TTM) | -188.02 M |
| Levered Free Cash Flow (TTM) | -120.81 M |
| Return on Assets (TTM) | -19.65% |
| Return on Equity (TTM) | -27.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Apogee Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 7.62% |
| % Held by Institutions | 137.71% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 116.00 (Guggenheim, 183.55%) | Buy |
| Median | 87.00 (112.66%) | |
| Low | 60.00 (RBC Capital, 46.66%) | Buy |
| Average | 87.67 (114.30%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 39.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 25 Sep 2025 | 60.00 (46.66%) | Buy | 37.52 |
| B of A Securities | 28 Aug 2025 | 87.00 (112.66%) | Buy | 36.62 |
| Guggenheim | 02 Jul 2025 | 116.00 (183.55%) | Buy | 44.32 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |